Andere talen Immutep ADR Nasdaq

Aandelen

IMMP

US45257L1089

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,01 ^USD	+7,49%		-26,64%	-16,25%

27/06	Wall Street zal donderdag marginaal lager openen als beleggers bullish economische cijfers analyseren	MT
27/06	Immutep rapporteert positieve resultaten in geneesmiddelencombinatiestudie voor hoofd-halskanker	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	28/06
ADRs End Flat; Alarum Technologies Climbs 26%	27/06
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	27/06
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer	27/06
Immutep Limited (IMM) \| TACTI-003: the real results; Maintain Overweight A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)	27/06
Immutep : Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC	27/06
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules	25/06
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	25/06
Immutep Signs Agreement with Cardiff University for Development Cancer Treatment	25/06
Immutep Completes Nearly AU$11 Million Retail Entitlement Offer	24/06
Immutep Completes Stock Offering	05/06
Immutep : successfully completes institutional placement and institutional component of entitlement offer	05/06
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	03/06
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	03/06
Immutep Raising AU$100 Million for Phase Three Trial	03/06
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	03/06
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	03/06
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15/05
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15/05
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immutep ADR Nasdaq

Aandelen

IMMP

US45257L1089

Andere talen

Filters